Map shows more than 1,100 measles cases across U.S.
The United States has recorded the most measles cases in a single year since a 2019 wave, and the number continues to grow, Centers for Disease Control and Prevention data shows. The majority of the infections have been reported in an outbreak in West Texas that has led to the deaths of two children.
The number of cases in Texas alone has grown to at least 750, while total cases nationwide have passed 1,197, with infections confirmed in at least 32 states.
Measles is one of the most contagious infectious diseases, and in some cases can cause severe infections in the lungs and brain that can lead to cognitive issues, deafness or death. But doctors and health officials say the vaccine, which is normally given as part of the combination measles-mumps-rubella (MMR) vaccine, is highly safe and effective.
While most people's symptoms improve, about 1 in 5 unvaccinated people who get measles will be hospitalized. About 1 out of every 1,000 children with measles will develop brain swelling that can lead to brain damage, and up to 3 of every 1,000 children who become infected will die, the CDC says.
The largest outbreak so far this year has been in West Texas, but cases have been reported in other states around the country, as well.
The CBS News data team is tracking confirmed measles cases nationwide as new data is released by state health departments and the CDC. (The map below is updated on Fridays when the CDC releases its latest weekly numbers.)
The Texas outbreak is primarily affecting children and teenagers, nearly all of whom were unvaccinated or have an unknown vaccination status. State and local health officials confirmed the first patient who died was an unvaccinated school-aged child, and the second was an unvaccinated 8-year-old girl. Neither of the children had underlying health conditions, the Texas health department said. New Mexico also reported the death of an adult with measles.
The last measles death in the U.S. before this year was in 2019, when a 37-year-old man died from measles complicated by meningitis in California, according to CDC data.
The highest number of confirmed cases in the U.S. in recent years was 1,274 in 2019, driven by outbreaks in New York, California and Washington state, but most years the total has been much lower.
Health experts point to lower vaccination rates as a reason for increases in preventable diseases like the measles.
CDC data shows about 93% of kindergarteners in the U.S. were vaccinated against measles during the 2021-2022 school year and only 92.7% in the 2023-2024 school year. This is down from 95.2% during the 2019-2020 school year — a critical threshold to keep people safe.
"When more than 95% of people in a community are vaccinated, most people are protected through community immunity (herd immunity)," the CDC states.
Health and Human Services Secretary Robert F. Kennedy Jr., who has a history of making false and misleading claims about vaccines, voiced support for vaccination as the deadly outbreak spread in the Southwest.
"We encourage people to get the measles vaccine," Kennedy told CBS News chief medical correspondent Dr. Jon LaPook in an interview April 8, marking the first time Kennedy has publicly urged people to get the measles vaccine since becoming HHS secretary.
Asked by LaPook what the federal government's official position on the vaccine is, Kennedy reiterated, "The federal government's position, my position, is that people should get the measles vaccine," but added, "The government should not be mandating those."
Teen questioned after family's quadruple murder
Israel claims new intel about Iran's nuclear capability spurred attack
Trump wraps Situation Room meeting on Israel-Iran conflict

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
AI Meets Oncology: Caris Life Sciences' $5.35B IPO Tests Investor Appetite for Precision Medicine
Caris Life Sciences, an AI-driven precision oncology company, is targeting a $5.35 billion valuation in its U.S. initial public offering, aiming to raise up to $423.5 million. The Irving, Texas-based firm, backed by investment giants Sixth Street and Neuberger Berman, has already conducted 6.5 million molecular tests across 849,000 patient cases, establishing partnerships with over 100 biopharmaceutical firms, including Moderna Inc (NASDAQ:MRNA) and AbbVie (NYSE:ABBV), according to its prospectus filed with the U.S. Securities and Exchange Commission. Don't Miss: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — Inspired by Uber and Airbnb – Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets – The $5.35 billion target—based on 23.5 million shares priced between $16 and $18 each—marks a notable shift from Caris' 2021 private valuation of $7.83 billion, Reuters reported, reflecting both market recalibration and the challenges of commercializing precision medicine. According to its filing, Caris generated $412.3 million in revenue in 2024—a 35% year-over-year increase—while posting a net loss of $257.1 million. In Q1 2025, the company reported $120.9 million in revenue and a narrowed net loss of $127 million, compared to $80.7 million in revenue and a $134.1 million loss during the same period in 2024, according to its filing—signaling improving margins and sustained top-line growth. At its proposed valuation, Caris would trade at approximately 13 times sales, a premium to peers like Guardant Health (NASDAQ: GH) and Tempus AI (NASDAQ: TEM), Reuters reported. Trending: Invest where it hurts — and help millions heal:. According to the company's website, Caris was founded in 2008 by entrepreneur David D. Halbert, who was inspired by his father's cancer battle to develop more effective, data-driven diagnostics. Today, the company operates from its North Texas headquarters and has offices in Phoenix, New York, Cambridge, Massachusetts, Tokyo, Japan, and Basel, Switzerland, serving both U.S. and international markets. Caris' proprietary AI platform, which integrates molecular science with machine learning, analyzes comprehensive genomic, transcriptomic, and proteomic data to guide cancer treatment. The company holds 27 issued patents along with over 170 applications pending worldwide, according to its website. Its flagship MI Cancer Seek test, cleared by the U.S. Food and Drug Administration in 2023, detects early-stage malignancies with what the company claims is unmatched accuracy, the company said at the time. Caris will trade on the Nasdaq under the symbol CAI The offering is led by BofA Securities, J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, and Citigroup Global Markets. Grand View Research projects a 22.5% CAGR in the AI cancer diagnostics market through 2030, highlighting strong growth potential in this Berman has indicated it may purchase up to $75 million worth of shares in the IPO—signaling insider confidence in the company's long-term potential, according to Reuters. Caris Life Sciences currently has one FDA-cleared diagnostic test, MI Cancer Seek, according to its filing. Caris' pipeline includes investigational tools like FOLFIRSTai, an AI-based test for predicting chemotherapy response in metastatic colorectal cancer. While clinically validated, it remains unapproved by the FDA, according to the SEC filing, and stricter regulations could delay its commercialization. Caris's proposed IPO is drawing attention as a potential marker for the viability of AI-driven healthcare, with Reuters noting the offering comes amid renewed interest in precision diagnostics. Read Next: Here's what Americans think you need to be considered wealthy. Peter Thiel turned $1,700 into $5 billion—now accredited investors are eyeing this software company with similar breakout potential. Learn how you can Image: Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? MODERNA (MRNA): Free Stock Analysis Report This article AI Meets Oncology: Caris Life Sciences' $5.35B IPO Tests Investor Appetite for Precision Medicine originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.


WebMD
an hour ago
- WebMD
More Adults Can Now Get Moderna's RSV Shot
June 17, 2025 – The FDA has expanded the use of Moderna's respiratory syncytial virus (RSV) shot to all adults, with some limits on who can get it. First approved in 2024 for people 60 or older, the mRESVIA vaccine protects against lower respiratory infections caused by RSV. This vaccine is now approved for adults ages 18 to 59 who have a higher risk of getting a serious RSV illness. RSV is a common virus that spreads easily in colder months through coughs, sneezes, or contact with contaminated surfaces. While it usually causes mild cold-like symptoms, it can be serious for babies and older adults. Vaccines and other preventive treatments offer the best protection against RSV. Moderna said the approval was supported by a study showing the vaccine is safe and works well for younger adults (ages 18 to 59) with medical conditions. Their immune response was just as strong as in older adults (60+), who had been studied earlier. All younger adults produced similar levels of protective antibodies against the two main types of RSV (RSV-A and RSV-B), showing the vaccine works well across at-risk adults of different ages. mRESVIA is an RNA vaccine that trains the body to make a harmless version of a protein used by the respiratory syncytial virus to enter human cells. This helps the immune system recognize the virus and build antibodies to protect against future infections. The vaccine does not contain RSV, so it cannot cause RSV illness. In clinical trials, the shot was generally well-tolerated. The most common side effects were mild and included pain where the needle went in, tiredness, headaches, muscle aches, joint pain, chills, nausea or vomiting, fever, and hives. Moderna plans to make mRESVIA available in the U.S. for the 2025-2026 respiratory virus season for high-risk adults ages 18 to 59 and all adults age 60 or older. Patients should tell their health care provider about any medical conditions they may have before getting the vaccine. This includes allergies, any serious reactions to vaccines in the past, current fever, any bleeding disorder or use of blood thinners, and a weakened immune system or use of medications that affect it. Patients should also say if they've already received another RSV vaccine or if they've ever fainted after getting a shot. There is a very small chance that mRESVIA can cause a severe allergic reaction, so patients may be asked to stay a while for observation after the shot.
Yahoo
an hour ago
- Yahoo
Dismissed vaccine advisers: Removals left program ‘critically weakened'
The members of a key federal vaccine advisory panel who were unceremoniously dismissed earlier this month said the recent actions of the Trump administration have 'critically weakened' the U.S. vaccine program, undermining decades of successful vaccine policy. In an opinion piece published in the JAMA medical journal, the former members of the Advisory Committee on Immunization Practices (ACIP) for the Centers for Disease Control and Prevention (CDC) spoke out directly against Health Secretary Robert F. Kennedy Jr.'s decision. Kennedy announced this month he was removing all 17 members of ACIP, saying, 'A clean sweep is needed to re-establish public confidence in vaccine science.' But the terminated members pushed back on this narrative. 'Health care providers and the US public trust ACIP. For the past 18 years, the National Immunization Survey has shown that 99 of every 100 children in the US have received at least some recommended vaccines by 2 years of age, consistent with acceptance of ACIP recommendations implemented by trusted clinicians,' wrote the former members. 'This does not suggest the population is so distrustful that it warrants dismantling the process by which vaccines have been recommended,' they added. They noted that meetings and agendas were all publicly available, potential conflicts of interest were regularly reviewed, and public comment was included in the committee's activities. 'The abrupt dismissal of the entire membership of the ACIP, along with its executive secretary, on June 9, 2025, the appointment of 8 new ACIP members just 2 days later, and the recent reduction of CDC staff dedicated to immunizations have left the US vaccine program critically weakened,' their op-ed continued. 'These actions have stripped the program of the institutional knowledge and continuity that have been essential to its success over decades.' The eight new members chosen by Kennedy include COVID-19 contrarians who are known to have spread vaccine misinformation. Along with their dismissal, the former 17 members also pointed to the changes Kennedy has made to COVID-19 vaccine policy as signs of a 'troubling disregard for the scientific integrity that has historically guided US immunization strategy.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.